Findings

What do systematic reviews say?

149 questions · 155 findings · 39 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 20 · 12.9%GRADE not reported 3 · 1.9%Very low 29 · 18.7%Low 45 · 29%Moderate 52 · 33.5%High 6 · 3.9%

Treatment route: intravenous corticosteroid vs oral corticosteroid

Length of hospitalisation (days) · exacerbations of COPD

1 finding from 1 review

Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease 2014 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 298 participants
Low

Treatment route: intravenous corticosteroid vs oral corticosteroid

Adverse drug effect—hyperglycaemia · exacerbations of COPD

Treatment route: intravenous corticosteroid probably leads to higher adverse drug effect ‐ hyperglycaemia compared with oral corticosteroid (moderate certainty).

1 finding from 1 review

Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease 2014 · Cochrane Headline outcomes only
OR 4.89 [1.2, 19.94]
1 study · 40 participants
Moderate

Treatment route: intravenous corticosteroid vs oral corticosteroid

Arterial blood gas tension: PaO2 after 3 months mmHg · exacerbations of COPD

1 finding from 1 review

Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Low

Treatment route: intravenous corticosteroid vs oral corticosteroid

Treatment failure Need for additional treatment · exacerbations of COPD

Treatment route: intravenous corticosteroid showed no clear difference in treatment failure Need to intensify therapy compared with oral corticosteroid (moderate certainty).

1 finding from 1 review

Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease 2014 · Cochrane Headline outcomes only
OR 0.67 [0.34, 1.3]
3 studies · 298 participants
Moderate

Treatment route: intravenous corticosteroid vs oral corticosteroid

Relapse Hospital readmission for COPD · exacerbations of COPD

Treatment route: intravenous corticosteroid showed no clear difference in relapse Hospital readmission for COPD compared with oral corticosteroid (moderate certainty).

1 finding from 1 review

Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease 2014 · Cochrane Headline outcomes only
OR 0.95 [0.5, 1.8]
3 studies · 298 participants
Moderate

Treatment route: intravenous corticosteroid vs oral corticosteroid

Breathlessness ‐ early effect VAS 0‐10. Scale from: 0 to 10. · exacerbations of COPD

1 finding from 1 review

Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 75 participants
Low

Any ICS vs oral corticosteroid

Asthma relapse1at 16 to 21 days · patients with acute asthma following emergency department discharge

Any ICS showed no clear difference in asthma relapse1at 16 to 21 days compared with oral corticosteroid (moderate certainty).

1 finding from 1 review

Inhaled steroids for acute asthma following emergency department discharge 2012 · Cochrane Headline outcomes only
OR 1.26 [0.8, 1.99]
2 studies · 425 participants
Moderate

Any ICS vs oral corticosteroid

Hospital admissions · patients with acute asthma following emergency department discharge

Any ICS showed no clear difference in hospital admission compared with oral corticosteroid (moderate certainty).

1 finding from 1 review

Inhaled steroids for acute asthma following emergency department discharge 2012 · Cochrane Headline outcomes only
OR 0.31 [0.01, 7.95]
3 studies · 254 participants
Moderate

Any ICS vs oral corticosteroid

Hoarseness at 16 to 21 days · patients with acute asthma following emergency department discharge

Any ICS showed no clear difference in hoarseness at 16 to 21 days compared with oral corticosteroid (low certainty).

1 finding from 1 review

Inhaled steroids for acute asthma following emergency department discharge 2012 · Cochrane Headline outcomes only
OR 1.62 [0.52, 5.05]
1 study · 412 participants
Low